About 6 results found for searched term "60-89-9" (0.128 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M1744 | ARRY-162 (Binimetinib) | MEK |
| MEK-162; Binimetinib; ARRY-438162 | ||
| ARRY-162 (MEK-162; Binimetinib) is a selective, potent inhibitor of MEK and cellular pERK with IC50 of 12 nM and 11 nM, respectively. | ||
| M11114 | Hosenkoside K | Others |
| Hosenkoside K is a glycoside isolated from the seeds of hydrangea flowers. | ||
| M24720 | Taldefgrobep alfa | Others |
| BMS 986089; RG 6206; RO 7239361 | ||
| Taldefgrobep alfa (BMS 986089; RG 6206; RO 7239361) is a potent inhibitory antibody targeting to human myostatin. Taldefgrobep alfa is a fusion protein composed of a human IgG1-Fc domain and Adnectin domain. Taldefgrobep alfa can be used for spinal muscular atrophy (SMA) research. | ||
| M45232 | Mepazine | MALT1 |
| Pecazine | ||
| Mepazine is a potent and selective inhibitor of MALT1 protease, with IC50s of 0.83 and 0.42 μM for inhibition of full-length GSTMALT1 and GSTMALT1 325-760 segments, respectively, and also affects the viability of ABC-DLBCL cells by enhancing apoptosis. Mepazine also affects the viability of ABC-DLBCL cells by enhancing apoptosis. | ||
| M28003 | BMS-986094 | Anti-infection |
| INX-08189 | ||
| BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate proagent of 6-O-methyl-2’-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection. | ||
| M30728 | TM6089 | HIF |
| TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
